Cargando…
A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
BACKGROUND: Patient decision aids (PDAs) are tools designed to facilitate decision-making. In this systematic review, we summarized existing studies on the development and evaluation of PDAs for patients with hematologic malignancies. PATIENTS AND METHODS: We followed the Preferred Reporting Items f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907042/ https://www.ncbi.nlm.nih.gov/pubmed/36342114 http://dx.doi.org/10.1093/oncolo/oyac231 |
_version_ | 1784884091378728960 |
---|---|
author | Zhao, Janice Abdallah, Maya Sanapala, Chandrika Watson, Erin LoCastro, Marissa Castillo, Daniel A Richardson, Daniel LeBlanc, Thomas W Loh, Kah Poh |
author_facet | Zhao, Janice Abdallah, Maya Sanapala, Chandrika Watson, Erin LoCastro, Marissa Castillo, Daniel A Richardson, Daniel LeBlanc, Thomas W Loh, Kah Poh |
author_sort | Zhao, Janice |
collection | PubMed |
description | BACKGROUND: Patient decision aids (PDAs) are tools designed to facilitate decision-making. In this systematic review, we summarized existing studies on the development and evaluation of PDAs for patients with hematologic malignancies. PATIENTS AND METHODS: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched for articles in PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. We included studies, abstracts, and clinical trial protocols available in English involving PDAs for patients age ≥18 diagnosed with a hematologic malignancy and/or their caregivers. Data were summarized using descriptive statistics. RESULTS: Of the 5281 titles/abstracts screened, 15 were included: 1 protocol, 7 abstracts, and 7 full-texts. Six were PDA developmental studies, 6 were pilot studies, and 3 were randomized trials. PDA formats included electronic with web content, videos, and/or audio, questionnaires, bedside instruments, and a combination of various formats. Average participant age ranged from 36.0 to 62.4 years. Patients and caregivers identified efficacy, adverse effects, cost, and quality of life as important decision-making factors. PDAs were associated with increased knowledge and patient satisfaction as well as decreased decisional conflict and attitudinal barriers. Research on PDAs for adult patients with hematologic malignancies and their caregivers is limited. Among the studies, PDAs appear to support patients in shared decision-making. CONCLUSION: While current literature examining the use of PDAs for adults with hematologic malignancies is limited, the positive impact of PDAs on shared decision-making and patient outcomes warrants additional research in this field. |
format | Online Article Text |
id | pubmed-9907042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-99070422023-02-09 A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? Zhao, Janice Abdallah, Maya Sanapala, Chandrika Watson, Erin LoCastro, Marissa Castillo, Daniel A Richardson, Daniel LeBlanc, Thomas W Loh, Kah Poh Oncologist Hematologic Malignancies BACKGROUND: Patient decision aids (PDAs) are tools designed to facilitate decision-making. In this systematic review, we summarized existing studies on the development and evaluation of PDAs for patients with hematologic malignancies. PATIENTS AND METHODS: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched for articles in PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. We included studies, abstracts, and clinical trial protocols available in English involving PDAs for patients age ≥18 diagnosed with a hematologic malignancy and/or their caregivers. Data were summarized using descriptive statistics. RESULTS: Of the 5281 titles/abstracts screened, 15 were included: 1 protocol, 7 abstracts, and 7 full-texts. Six were PDA developmental studies, 6 were pilot studies, and 3 were randomized trials. PDA formats included electronic with web content, videos, and/or audio, questionnaires, bedside instruments, and a combination of various formats. Average participant age ranged from 36.0 to 62.4 years. Patients and caregivers identified efficacy, adverse effects, cost, and quality of life as important decision-making factors. PDAs were associated with increased knowledge and patient satisfaction as well as decreased decisional conflict and attitudinal barriers. Research on PDAs for adult patients with hematologic malignancies and their caregivers is limited. Among the studies, PDAs appear to support patients in shared decision-making. CONCLUSION: While current literature examining the use of PDAs for adults with hematologic malignancies is limited, the positive impact of PDAs on shared decision-making and patient outcomes warrants additional research in this field. Oxford University Press 2022-11-07 /pmc/articles/PMC9907042/ /pubmed/36342114 http://dx.doi.org/10.1093/oncolo/oyac231 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Hematologic Malignancies Zhao, Janice Abdallah, Maya Sanapala, Chandrika Watson, Erin LoCastro, Marissa Castillo, Daniel A Richardson, Daniel LeBlanc, Thomas W Loh, Kah Poh A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? |
title | A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? |
title_full | A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? |
title_fullStr | A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? |
title_full_unstemmed | A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? |
title_short | A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? |
title_sort | systematic review of decision aids in hematologic malignancies: what are currently available and what are we missing? |
topic | Hematologic Malignancies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907042/ https://www.ncbi.nlm.nih.gov/pubmed/36342114 http://dx.doi.org/10.1093/oncolo/oyac231 |
work_keys_str_mv | AT zhaojanice asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT abdallahmaya asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT sanapalachandrika asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT watsonerin asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT locastromarissa asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT castillodaniela asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT richardsondaniel asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT leblancthomasw asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT lohkahpoh asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT zhaojanice systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT abdallahmaya systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT sanapalachandrika systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT watsonerin systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT locastromarissa systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT castillodaniela systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT richardsondaniel systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT leblancthomasw systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing AT lohkahpoh systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing |